ID   OGA_HUMAN               Reviewed;         916 AA.
AC   O60502; B7WPB9; D3DR79; E9PGF9; O75166; Q86WV0; Q8IV98; Q9BVA5;
AC   Q9HAR0;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 2.
DT   10-MAY-2017, entry version 136.
DE   RecName: Full=Protein O-GlcNAcase {ECO:0000303|PubMed:11148210, ECO:0000303|PubMed:11788610};
DE            Short=OGA {ECO:0000303|PubMed:20863279};
DE            EC=3.2.1.169 {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600, ECO:0000305|PubMed:20673219};
DE   AltName: Full=Beta-N-acetylglucosaminidase {ECO:0000303|PubMed:11148210};
DE            EC=3.2.1.- {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20673219, ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600};
DE   AltName: Full=Beta-N-acetylhexosaminidase;
DE   AltName: Full=Beta-hexosaminidase;
DE   AltName: Full=Meningioma-expressed antigen 5 {ECO:0000303|PubMed:9811929};
DE   AltName: Full=N-acetyl-beta-D-glucosaminidase;
DE   AltName: Full=N-acetyl-beta-glucosaminidase;
DE   AltName: Full=Nuclear cytoplasmic O-GlcNAcase and acetyltransferase;
DE            Short=NCOAT;
GN   Name=MGEA5; Synonyms=HEXC, KIAA0679, MEA5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Meningioma;
RX   PubMed=9811929; DOI=10.1093/hmg/7.12.1859;
RA   Heckel D., Comtesse N., Brass N., Blin N., Zang K.D., Meese E.;
RT   "Novel immunogenic antigen homologous to hyaluronidase in
RT   meningioma.";
RL   Hum. Mol. Genet. 7:1859-1872(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 3), SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11341771; DOI=10.1006/bbrc.2001.4815;
RA   Comtesse N., Maldener E., Meese E.;
RT   "Identification of a nuclear variant of MGEA5, a cytoplasmic
RT   hyaluronidase and a beta-N-acetylglucosaminidase.";
RL   Biochem. Biophys. Res. Commun. 283:634-640(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, ENZYME REGULATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=11148210; DOI=10.1074/jbc.M010420200;
RA   Gao Y., Wells L., Comer F.I., Parker G.J., Hart G.W.;
RT   "Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning
RT   and characterization of a neutral, cytosolic beta-N-
RT   acetylglucosaminidase from human brain.";
RL   J. Biol. Chem. 276:9838-9845(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LYS-602.
RC   TISSUE=Cervix, Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT,
RP   PTM, AND SUBCELLULAR LOCATION.
RX   PubMed=11788610; DOI=10.1074/jbc.M109656200;
RA   Wells L., Gao Y., Mahoney J.A., Vosseller K., Chen C., Rosen A.,
RA   Hart G.W.;
RT   "Dynamic O-glycosylation of nuclear and cytosolic proteins: further
RT   characterization of the nucleocytoplasmic beta-N-
RT   acetylglucosaminidase, O-GlcNAcase.";
RL   J. Biol. Chem. 277:1755-1761(2002).
RN   [10]
RP   ACTIVE SITE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-174 AND
RP   ASP-175.
RX   PubMed=16533067; DOI=10.1021/bi052370b;
RA   Cetinbas N., Macauley M.S., Stubbs K.A., Drapala R., Vocadlo D.J.;
RT   "Identification of Asp174 and Asp175 as the key catalytic residues of
RT   human O-GlcNAcase by functional analysis of site-directed mutants.";
RL   Biochemistry 45:3835-3844(2006).
RN   [11]
RP   PTM, SITE, MUTAGENESIS OF ASP-413, AND CATALYTIC ACTIVITY.
RX   PubMed=18586680; DOI=10.1074/jbc.M804116200;
RA   Butkinaree C., Cheung W.D., Park S., Park K., Barber M., Hart G.W.;
RT   "Characterization of beta-N-acetylglucosaminidase cleavage by caspase-
RT   3 during apoptosis.";
RL   J. Biol. Chem. 283:23557-23566(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-69; ASP-175;
RP   VAL-255; TYR-286; ASP-287 AND TRP-679.
RX   PubMed=20863279; DOI=10.1042/BJ20101338;
RA   Schimpl M., Schuttelkopf A.W., Borodkin V.S., van Aalten D.M.;
RT   "Human OGA binds substrates in a conserved peptide recognition
RT   groove.";
RL   Biochem. J. 432:1-7(2010).
RN   [16]
RP   FUNCTION OF ISOFORMS 1 AND 3, AND CATALYTIC ACTIVITY.
RX   PubMed=20673219; DOI=10.1134/S0006297910070175;
RA   Li J., Huang C.L., Zhang L.W., Lin L., Li Z.H., Zhang F.W., Wang P.;
RT   "Isoforms of human O-GlcNAcase show distinct catalytic efficiencies.";
RL   Biochemistry (Mosc.) 75:938-943(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   LACK OF ACETYLTRANSFERASE ACTIVITY, AND FUNCTION.
RX   PubMed=24088714; DOI=10.1098/rsob.130021;
RA   Rao F.V., Schuttelkopf A.W., Dorfmueller H.C., Ferenbach A.T.,
RA   Navratilova I., van Aalten D.M.;
RT   "Structure of a bacterial putative acetyltransferase defines the fold
RT   of the human O-GlcNAcase C-terminal domain.";
RL   Open Biol. 3:130021-130021(2013).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 402-408, MUTAGENESIS OF
RP   TYR-69, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22365600; DOI=10.1016/j.chembiol.2012.01.011;
RA   Schimpl M., Borodkin V.S., Gray L.J., van Aalten D.M.;
RT   "Synergy of peptide and sugar in O-GlcNAcase substrate recognition.";
RL   Chem. Biol. 19:173-178(2012).
CC   -!- FUNCTION: Isoform 1: Cleaves GlcNAc but not GalNAc from O-
CC       glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-
CC       methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-
CC       beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro)
CC       (PubMed:11148210). Does not bind acetyl-CoA and does not have
CC       histone acetyltransferase activity (PubMed:24088714).
CC       {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610,
CC       ECO:0000269|PubMed:20673219, ECO:0000269|PubMed:22365600,
CC       ECO:0000269|PubMed:24088714}.
CC   -!- FUNCTION: Isoform 3: Cleaves GlcNAc but not GalNAc from O-
CC       glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as
CC       substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-
CC       alpha-GlcNAc (in vitro), but has about six times lower specific
CC       activity than isoform 1. {ECO:0000269|PubMed:20673219}.
CC   -!- CATALYTIC ACTIVITY: [Protein]-3-O-(N-acetyl-beta-D-glucosaminyl)-
CC       L-serine + H(2)O = [protein]-L-serine + N-acetyl-D-glucosamine.
CC       {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610,
CC       ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20863279,
CC       ECO:0000269|PubMed:22365600, ECO:0000305|PubMed:20673219}.
CC   -!- CATALYTIC ACTIVITY: [Protein]-3-O-(N-acetyl-beta-D-glucosaminyl)-
CC       L-threonine + H(2)O = [protein]-L-threonine + N-acetyl-D-
CC       glucosamine. {ECO:0000269|PubMed:11148210,
CC       ECO:0000269|PubMed:11788610, ECO:0000269|PubMed:18586680,
CC       ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600,
CC       ECO:0000305|PubMed:20673219}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal non-reducing N-acetyl-
CC       D-hexosamine residues in N-acetyl-beta-D-hexosaminides.
CC       {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11788610,
CC       ECO:0000269|PubMed:18586680, ECO:0000269|PubMed:20673219,
CC       ECO:0000269|PubMed:20863279, ECO:0000269|PubMed:22365600}.
CC   -!- ENZYME REGULATION: Inhibited by N-acetylglucosamine and not N-
CC       acetylgalactosamine. {ECO:0000269|PubMed:11148210}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.1 mM for pNP-GlcNAc {ECO:0000269|PubMed:11788610};
CC         Vmax=652 umol/min/mg enzyme with pNP-GLcNAc as substrate
CC         {ECO:0000269|PubMed:11788610};
CC       pH dependence:
CC         Optimum pH is 5.7-7. {ECO:0000269|PubMed:11148210};
CC   -!- SUBUNIT: Monomer (PubMed:11788610). Interacts with CLOCK (By
CC       similarity). {ECO:0000250|UniProtKB:Q9EQQ9,
CC       ECO:0000269|PubMed:11788610}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus
CC       {ECO:0000269|PubMed:11341771}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm
CC       {ECO:0000269|PubMed:11148210, ECO:0000269|PubMed:11341771,
CC       ECO:0000269|PubMed:11788610}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O60502-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60502-2; Sequence=VSP_020866, VSP_020869;
CC       Name=3; Synonyms=MGEA5s;
CC         IsoId=O60502-3; Sequence=VSP_020867, VSP_020868;
CC       Name=4;
CC         IsoId=O60502-4; Sequence=VSP_020866;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Shows highest expression in the
CC       brain, placenta and pancreas. {ECO:0000269|PubMed:11148210,
CC       ECO:0000269|PubMed:11341771}.
CC   -!- PTM: Proteolytically cleaved by caspase-3 during apoptosis. The
CC       fragments interact with each other; cleavage does not decrease
CC       enzyme activity. {ECO:0000269|PubMed:11788610,
CC       ECO:0000269|PubMed:18586680}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 84 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: The mouse and rat orthologs were initially identified as
CC       bi-functional proteins containing an N-terminal domain with O-
CC       GlcNAcase activity and a C-terminal domain with histone
CC       acetyltransferase activity. The histone acetyltransferase activity
CC       was detected only when the protein was expressed in mammalian
CC       cells, but not when expressed in bacterial cells, suggesting that
CC       the histone acetyltransferase activity might be due to the
CC       presence of a contaminant. Comparison of the human protein with a
CC       bacterial putative acetyltransferase (AC Q2CEE2) shows that the
CC       residues important for acetyl-CoA binding are not conserved, and
CC       that the residues proposed to be important for histone
CC       acetyltransferase activity are not in a position where they could
CC       participate in catalysis. Characterization of the human protein
CC       shows that it does not bind acetyl-CoA and therefore cannot have
CC       acetyltransferase activity. {ECO:0000269|PubMed:24088714,
CC       ECO:0000305|PubMed:24088714}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH47877.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA31654.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF036144; AAD05385.2; -; mRNA.
DR   EMBL; AF307332; AAG21428.1; -; mRNA.
DR   EMBL; AB014579; BAA31654.2; ALT_INIT; mRNA.
DR   EMBL; AC010789; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49744.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49741.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49742.1; -; Genomic_DNA.
DR   EMBL; BC001343; AAH01343.1; -; mRNA.
DR   EMBL; BC039583; AAH39583.2; -; mRNA.
DR   EMBL; BC047877; AAH47877.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS44471.1; -. [O60502-4]
DR   CCDS; CCDS7520.1; -. [O60502-1]
DR   PIR; T00360; T00360.
DR   RefSeq; NP_001135906.1; NM_001142434.1. [O60502-4]
DR   RefSeq; NP_036347.1; NM_012215.3. [O60502-1]
DR   UniGene; Hs.500842; -.
DR   PDB; 2YDQ; X-ray; 2.60 A; T=402-408.
DR   PDB; 5M7R; X-ray; 2.35 A; A/B=1-916.
DR   PDB; 5M7S; X-ray; 2.40 A; A/B=1-916.
DR   PDB; 5M7T; X-ray; 2.60 A; A/B=1-916.
DR   PDB; 5M7U; X-ray; 2.30 A; A/B=1-916.
DR   PDB; 5TKE; X-ray; 2.48 A; A/B=60-400, A/B=553-704.
DR   PDB; 5UHK; X-ray; 2.97 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHL; X-ray; 3.14 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHO; X-ray; 3.21 A; A/C=56-400, B/D=544-705.
DR   PDB; 5UHP; X-ray; 2.79 A; A/B/C/D=14-400, E/F/G/H=554-705.
DR   PDB; 5UN8; X-ray; 2.13 A; A/B/C/D=60-400, A/B/C/D=553-704.
DR   PDB; 5UN9; X-ray; 2.50 A; A/B=60-400, A/B=553-704.
DR   PDBsum; 2YDQ; -.
DR   PDBsum; 5M7R; -.
DR   PDBsum; 5M7S; -.
DR   PDBsum; 5M7T; -.
DR   PDBsum; 5M7U; -.
DR   PDBsum; 5TKE; -.
DR   PDBsum; 5UHK; -.
DR   PDBsum; 5UHL; -.
DR   PDBsum; 5UHO; -.
DR   PDBsum; 5UHP; -.
DR   PDBsum; 5UN8; -.
DR   PDBsum; 5UN9; -.
DR   ProteinModelPortal; O60502; -.
DR   SMR; O60502; -.
DR   BioGrid; 115948; 33.
DR   IntAct; O60502; 20.
DR   STRING; 9606.ENSP00000354850; -.
DR   BindingDB; O60502; -.
DR   ChEMBL; CHEMBL5921; -.
DR   CAZy; GH84; Glycoside Hydrolase Family 84.
DR   iPTMnet; O60502; -.
DR   PhosphoSitePlus; O60502; -.
DR   BioMuta; MGEA5; -.
DR   EPD; O60502; -.
DR   MaxQB; O60502; -.
DR   PaxDb; O60502; -.
DR   PeptideAtlas; O60502; -.
DR   PRIDE; O60502; -.
DR   DNASU; 10724; -.
DR   Ensembl; ENST00000357797; ENSP00000350445; ENSG00000198408. [O60502-2]
DR   Ensembl; ENST00000361464; ENSP00000354850; ENSG00000198408. [O60502-1]
DR   Ensembl; ENST00000370094; ENSP00000359112; ENSG00000198408. [O60502-3]
DR   Ensembl; ENST00000439817; ENSP00000409973; ENSG00000198408. [O60502-4]
DR   GeneID; 10724; -.
DR   KEGG; hsa:10724; -.
DR   UCSC; uc001ktv.3; human. [O60502-1]
DR   CTD; 10724; -.
DR   DisGeNET; 10724; -.
DR   GeneCards; MGEA5; -.
DR   HGNC; HGNC:7056; MGEA5.
DR   HPA; HPA036141; -.
DR   HPA; HPA076501; -.
DR   MIM; 604039; gene.
DR   neXtProt; NX_O60502; -.
DR   OpenTargets; ENSG00000198408; -.
DR   PharmGKB; PA30787; -.
DR   eggNOG; KOG3698; Eukaryota.
DR   eggNOG; ENOG410XPBQ; LUCA.
DR   GeneTree; ENSGT00390000007726; -.
DR   HOVERGEN; HBG053044; -.
DR   InParanoid; O60502; -.
DR   KO; K15719; -.
DR   OMA; QFGCEAY; -.
DR   OrthoDB; EOG091G02T9; -.
DR   PhylomeDB; O60502; -.
DR   TreeFam; TF313732; -.
DR   BioCyc; MetaCyc:HS03036-MONOMER; -.
DR   BRENDA; 3.2.1.35; 2681.
DR   ChiTaRS; MGEA5; human.
DR   GeneWiki; MGEA5; -.
DR   GenomeRNAi; 10724; -.
DR   PMAP-CutDB; O60502; -.
DR   PRO; PR:O60502; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000198408; -.
DR   CleanEx; HS_MGEA5; -.
DR   ExpressionAtlas; O60502; baseline and differential.
DR   Genevisible; O60502; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0102571; F:[protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine/L-threonine O-N-acetyl-alpha-D-glucosaminase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016231; F:beta-N-acetylglucosaminidase activity; IDA:UniProtKB.
DR   GO; GO:0004415; F:hyalurononglucosaminidase activity; TAS:ProtInc.
DR   GO; GO:0006516; P:glycoprotein catabolic process; TAS:ProtInc.
DR   GO; GO:0006044; P:N-acetylglucosamine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006517; P:protein deglycosylation; IDA:UniProtKB.
DR   GO; GO:0006493; P:protein O-linked glycosylation; NAS:ParkinsonsUK-UCL.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR011496; Beta-N-acetylglucosaminidase.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Pfam; PF07555; NAGidase; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Glycosidase; Hydrolase; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    916       Protein O-GlcNAcase.
FT                                /FTId=PRO_0000252118.
FT   REGION      278    280       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q2CEE3}.
FT   ACT_SITE    175    175       Proton donor.
FT                                {ECO:0000305|PubMed:16533067}.
FT   BINDING      67     67       Substrate; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q2CEE3}.
FT   BINDING      98     98       Substrate.
FT                                {ECO:0000250|UniProtKB:Q0TR53}.
FT   BINDING     174    174       Substrate.
FT                                {ECO:0000250|UniProtKB:Q0TR53}.
FT   BINDING     219    219       Substrate.
FT                                {ECO:0000250|UniProtKB:Q2CEE3}.
FT   BINDING     285    285       Substrate.
FT                                {ECO:0000250|UniProtKB:Q2CEE3}.
FT   BINDING     313    313       Substrate.
FT                                {ECO:0000250|UniProtKB:Q2CEE3}.
FT   SITE        413    414       Cleavage; by caspase-3.
FT                                {ECO:0000269|PubMed:18586680}.
FT   MOD_RES     364    364       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     346    398       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_020866.
FT   VAR_SEQ     663    677       CRSHSSAQFLIGDQE -> RCTRNNLFSSNILSL (in
FT                                isoform 3). {ECO:0000303|PubMed:9811929}.
FT                                /FTId=VSP_020867.
FT   VAR_SEQ     678    916       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:9811929}.
FT                                /FTId=VSP_020868.
FT   VAR_SEQ     691    704       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_020869.
FT   VARIANT      46     46       G -> E (in dbSNP:rs3740421).
FT                                /FTId=VAR_027761.
FT   VARIANT     602    602       E -> K (in dbSNP:rs17853930).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_027762.
FT   MUTAGEN      69     69       Y->K,Q: Strongly reduces affinity for
FT                                glycopeptide substrates. Nearly abolishes
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:20863279,
FT                                ECO:0000269|PubMed:22365600}.
FT   MUTAGEN      69     69       Y->S: Strongly reduces affinity for
FT                                glycopeptide substrates. Nearly abolishes
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:20863279,
FT                                ECO:0000269|PubMed:22365600}.
FT   MUTAGEN     174    174       D->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16533067}.
FT   MUTAGEN     175    175       D->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16533067}.
FT   MUTAGEN     175    175       D->N: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:20863279}.
FT   MUTAGEN     255    255       V->G,T: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:20863279}.
FT   MUTAGEN     286    286       Y->S: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:20863279}.
FT   MUTAGEN     287    287       D->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:20863279}.
FT   MUTAGEN     413    413       D->A: Abrogates cleavage by caspase-3.
FT                                {ECO:0000269|PubMed:18586680}.
FT   MUTAGEN     679    679       W->N: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:20863279}.
SQ   SEQUENCE   916 AA;  102915 MW;  01F8A64A9B1475C6 CRC64;
     MVQKESQATL EERESELSSN PAASAGASLE PPAAPAPGED NPAGAGGAAV AGAAGGARRF
     LCGVVEGFYG RPWVMEQRKE LFRRLQKWEL NTYLYAPKDD YKHRMFWREM YSVEEAEQLM
     TLISAAREYE IEFIYAISPG LDITFSNPKE VSTLKRKLDQ VSQFGCRSFA LLFDDIDHNM
     CAADKEVFSS FAHAQVSITN EIYQYLGEPE TFLFCPTEYC GTFCYPNVSQ SPYLRTVGEK
     LLPGIEVLWT GPKVVSKEIP VESIEEVSKI IKRAPVIWDN IHANDYDQKR LFLGPYKGRS
     TELIPRLKGV LTNPNCEFEA NYVAIHTLAT WYKSNMNGVR KDVVMTDSED STVSIQIKLE
     NEGSDEDIET DVLYSPQMAL KLALTEWLQE FGVPHQYSSR QVAHSGAKAS VVDGTPLVAA
     PSLNATTVVT TVYQEPIMSQ GAALSGEPTT LTKEEEKKQP DEEPMDMVVE KQEETDHKND
     NQILSEIVEA KMAEELKPMD TDKESIAESK SPEMSMQEDC ISDIAPMQTD EQTNKEQFVP
     GPNEKPLYTA EPVTLEDLQL LADLFYLPYE HGPKGAQMLR EFQWLRANSS VVSVNCKGKD
     SEKIEEWRSR AAKFEEMCGL VMGMFTRLSN CANRTILYDM YSYVWDIKSI MSMVKSFVQW
     LGCRSHSSAQ FLIGDQEPWA FRGGLAGEFQ RLLPIDGAND LFFQPPPLTP TSKVYTIRPY
     FPKDEASVYK ICREMYDDGV GLPFQSQPDL IGDKLVGGLL SLSLDYCFVL EDEDGICGYA
     LGTVDVTPFI KKCKISWIPF MQEKYTKPNG DKELSEAEKI MLSFHEEQEV LPETFLANFP
     SLIKMDIHKK VTDPSVAKSM MACLLSSLKA NGSRGAFCEV RPDDKRILEF YSKLGCFEIA
     KMEGFPKDVV ILGRSL
//
